
==== Front
BMC Infect Dis
BMC Infect Dis
BMC Infectious Diseases
1471-2334
BioMed Central London

9895
10.1186/s12879-024-09895-9
Research
Clinical characteristics and prognostic factors of pulmonary and extrapulmonary cryptococcosis
Tao Ziwei 1
Pu Qinqin 2
Shen Yongli 2
Zhang Sicheng 3
Wang Chuanyou 1
Hu Zhe 1
Jin Yi 4
Zhu Xiaowu 13365517957@189.cn

1
Weng Yali wengyali@njmu.edu.cn

2
1 https://ror.org/04c4dkn09 grid.59053.3a 0000 0001 2167 9639 Department of Infectious Disease, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000 China
2 https://ror.org/04py1g812 grid.412676.0 0000 0004 1799 0784 Department of Infectious Disease, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029 China
3 https://ror.org/05qwgjd68 grid.477985.0 0000 0004 1757 6137 Department of Acute and Critical Care Medicine, Hefei First People’s Hospital, Hefei, 230001 China
4 Department of Gastroenterology, Jiangsu Provincial Rongjun Hospital, Wuxi, 214000 China
20 9 2024
20 9 2024
2024
24 101822 7 2024
6 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Cryptococcosis is progressively acknowledged among people, irrespective of the human with or without immunodeficiency virus (HIV). This change in epidemiology has been recorded in recent years, prompting closer examination and a broader understanding of the disease manifestations and risk factors.

Methods

The data of cryptococcal infections in China during 11 years were retrospectively analyzed. According to the position of infection, the patients were categorized into the pulmonary infection group and extrapulmonary infection group. The composition of the two groups was compared, and the potential risk factors of disseminated infection were analyzed. Logistic regression was used to analyze the prognostic risk factors of the disease.

Results

A total of 165 patients were enrolled. 113 (68.5%) were male, and the age was 47.49 (18–82) years. 101 cases (61.2%) had a normal immune function and 64 cases (38.8%) had impaired immune function. 45 patients had extrapulmonary infection, involving the central nervous system, bone and joint, skin and bloodstream, and 120 patients had simple pulmonary infection. The mortality of the extrapulmonary infection group (48.9%) was significantly higher than that of the pulmonary infection group (0.8%). According to univariate logistic regression analysis, immune status (hazard ratio [HR], 4.476; 95% confidence interval [CI], 1.725–11.618; P = 0.002), infection position ([HR], 113.826; [CI], 14.607-886.967; P < 0.001), white blood cell count, ([HR],1.209;[CI], 1.054–1.386; P = 0.007), hemoglobin ([HR], 0.970; [CI], 0.955–0.986; P < 0.001), platelet count ([HR], 0.993; [CI], 0.987–0.999; P = 0.026), neutrophil percentage ([HR], 1.115; [CI], 1.065–1.168; P < 0.001), lymphocyte percentage ([HR], 0.875; [CI], 0.827–0.927; P < 0.001), neutrophil-to-lymphocyte Ratio (NLR) ([HR], 1.144; [CI], 1.072–1.221; P < 0.001), monocyte percentage ([HR], 0.752; [CI], 0.618–0.915; P = 0.004) were related to the prognosis. Multivariate logistic regression analysis showed that the infection position was remained related to the prognosis with statistical significance ([HR], 0.018; [CI], 0.001–0.384; P = 0.001).

Conclusion

Extrapulmonary infection of Cryptococcosis is an important risk factor for prognosis. High levels of neutrophils and NLR, and low levels of lymphocytes and monocytes may lead to disseminated infection of Cryptococcosis. Further studies are needed to reduce the occurrence rate of extrapulmonary infection and mortality.

Keywords

Cryptococcus
Extrapulmonary infection
Pulmonary infection
Prognosis
Xiaowu Zhu famous doctor studioNO.CY2019002 NO.CY2019002 NO.CY2019002 NO.CY2019002 NO.CY2019002 NO.CY2019002 NO.CY2019002 NO.CY2019002 NO.CY2019002 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Cryptococcus is an opportunistic pathogenic yeast that is prevalent in the environment, thriving in pigeon guano, some plants (e.g. eucalyptus trees) and soil [1]. Normally, Cryptococcus in the environment invade the lungs through the respiratory tract, which is often confined to the lungs or resolved by the human innate immune system. However, Cryptococcus may cause life-threatening illnesses in immunocompromised individuals, such as cryptococcal meningitis (CM), either from reactivation of a previously acquired latent infection or novel exposure [2–4].

The mortality rate among patients with extrapulmonary cryptococcosis is extremely high, particularly in the case of CM, where the mortality rate can reach as high as 60–80% within 6 months after diagnosis [5]. Although, in recent years, it has not only been in those with HIV and natural or iatrogenic immunosuppression but also in apparently immunocompetent individuals [6–9]. In a previous study, it was reported that 67% of instances of pulmonary cryptococcosis among immunocompetent patients progressed to disseminate into the central nervous system, leading to CM, not to mention immunocompromised patients [10].

To further improve our comprehension of the manifestations and consequences of cryptococcosis diagnosed in Chinese people with or without HIV infection, we performed a retrospective study. The aim of this study is to compare the clinical characteristics and treatment strategies between pulmonary and extrapulmonary infection of Cryptococcus, explore the potential risk factors for the development of pulmonary cryptococcosis to CM, identify the prognostic factors of cryptococcosis, and provide new ideas for preventing extrapulmonary infection and improving the prognosis of patients.

Materials and methods

Research objects

One hundred and sixty-five patients diagnosed with cryptococcosis in the First Affiliated Hospital with Nanjing Medical University from January 2010 to December 2021 were included in the study, including 113 males and 52 females. Inclusion criteria: cryptococcal disease had to be “proven” by radiographic anomalies consistent with the disease, coupled with confirmed culture positivity from sterile fluid or biopsy confirmation. Alternatively, a diagnosis of “probable” cryptococcosis was assigned in cases exhibiting antigen positivity in blood or cerebrospinal fluid (CSF). Instances where microbial retrieval from sputum or bronchoalveolar lavage lacked concordance with clinical and/or radiographic evidence were categorized as “possible” pulmonary disease. Diseases involving the central nervous system (CNS) with evidence of Cryptococcus in histological examination, antigen detection, or culture of brain tissue or CSF were also included [11, 12]. The exclusion criteria: patients under the age of 18.

The study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by The Ethics Committee of The First Affiliated Hospital with Nanjing Medical University. Because it was a retrospective nature of the study with anonymized clinical data, the informed consent was waived.

Research methods

A retrospective analysis of the clinical data of 165 patients, including gender, age, immune status, comorbidities, clinical symptoms; laboratory indicators: blood routine examination, serum procalcitonin (PCT), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fasting plasma glucose; antifungal regimens; treatment efficacy, etc. Outcomes: all-cause case fatality at 30 days after the diagnosis.

Statistical methods

All data statistics used are carried out by SPSS 26.0 software. Count data were expressed as n (%) and χ2 test or Fisher’s exact probability test was used. Normally, distributed measurement data were expressed as x ± s and analyzed with independent samples t-test. Non-normally distributed measurement data were expressed as median (M) and interquartile range (Q1–Q3) indicates that the non-parametric test was used. Logistic regression analysis was used for multivariate analysis. P < 0.05 was considered statistically significant.

Results

General information

According to the inclusion and exclusion criteria, a total of 165 adult cases of cryptococcosis were screened, as shown in Fig. 1. Subject demographic characteristics, exposures, and immunosuppressive conditions are summarized in Table 1. Among 165 patients, 113 (68.5%) were male, the age was 47.49 (18–82) years, and 58 (35.2%) patients had a history of smoking. Normal immune function was observed in 101 cases (61.2%), whereas 64 cases (38.8%) exhibited impaired immune function. The majority of patients with abnormal immune status had conditions such as diabetes mellitus, autoimmune diseases, and glucocorticoid therapy.

Fig. 1 Flow chart of study sample selection

Table 1 Demographic characteristics of 165 patients with cryptococcosis

Variables	Values	
Mean age, (year)	47.49 (18–82)	
Male sex, no (%)	113 (68.5)	
Smoker, no (%)	58 (35.2)	
Alcohol, no (%)	32 (19.4)	
Underlying diseases, no (%)		
 Diabetes mellitus	27 (16.4)	
 Autoimmune disease	13 (7.9)	
 soild organ transplantation	7 (4.2)	
 Hematologic malignancy	5 (3.0)	
 Decompensated liver disease	3 (1.8)	
 Solid tumor	4 (2.4)	
 Invasive Fungal Infection history	3 (1.8)	
 Acquired immunodeficiency syndrome	8 (4.8)	
Immunosuppressive medications		
 Glucocorticoid therapy	16 (9.7)	
 Cytotoxic chemotherapy	6 (3.6)	
 Calcineurin/mTOR inhibitors	7 (4.2)	

Characteristics at admission

Of the 165 patients, 45 individuals were afflicted with extrapulmonary infection, which affected their central nervous system, bones and joints, skin, or bloodstream. Meanwhile, the remaining 120 patients suffered from a more straightforward pulmonary infection.

Upon analyzing the composition of the pulmonary infection group and the extrapulmonary infection group, it was observed that the proportion of patients with abnormal immune function in the extrapulmonary infection group was higher, and the clinical manifestations of the two groups were significantly different. The main manifestations of the pulmonary infection group were cough (57.5%), expectoration (38.4%), and chest pain (16.8%). In contrast, the extrapulmonary infection group primarily exhibited symptoms such as headache (80.0%), fever (68.9%), nervous system symptoms (57.8%), and vomiting (42.2%). Furthermore, in the laboratory examination, the percentage of neutrophils (82.5%) and NLR (6.7131) in the extrapulmonary infection group were higher, hemoglobin (115 g/L), platelet count (179.04 × 109/L) and lymphocyte percentage (14.17%) were lower. Additionally, an increase in PCT, CRP and fasting blood glucose was more common. (Table 2).

Table 2 Comparison of clinical characteristics between patients with cryptococcosis

	Total cohort (n = 165)	Pulmonary infection (n = 120)	Extrapulmonary infection(n = 45)	P Value	
Mean age, year (range)	47.49 (18–82)	47.6 (18–80)	47.2 (19–82)	0.866	
Male, no (%)	113 (68.5)	84 (70.0)	29 (64.4)	0.494	
Smoking, no (%)	58 (35.2)	45 (37.5)	13 (28.9)	0.302	
Alcohol drinking, no (%)	32 (19.4)	23 (19.2)	9 (20)	0.904	
Epidemiological, no (%)	8 (4.8)	5 (4.2)	3 (6.7)	0.796 b	
Immune status, no (%)	64 (38.8)	33 (27.5)	31 (68.9)	< 0.001	
Underlying diseases, no (%)					
 Diabetes mellitus	27 (16.4)	22 (18.3)	5 (11.1)	0.264	
 Autoimmune disease	13 (7.9)	5 (4.2)	8 (17.8)	0.010b	
 soild organ transplantation	7 (4.2)	1 (0.8)	6 (13.3)	0.002b	
 Hematologic malignancy	5 (3.0)	1 (0.8)	4 (8.9)	0.029b	
 Decompensated liver disease	3 (1.8)	1 (0.8)	2 (4.4)	0.372b	
 Solid tumor	4 (2.4)	4 (3.3)	0	0.502b	
 Invasive Fungal Infection history	3 (1.8)	1 (0.8)	2 (4.4)	0.372b	
 Acquired immunodeficiency syndrome	8 (4.8)	0	8 (17.8)	< 0.001b	
Immunosuppressive medications, no (%)					
 Glucocorticoid therapy	16 (9.7)	4 (3.3)	12 (26.7)	< 0.001b	
 Cytotoxic chemotherapy	6 (3.6)	2 (1.7)	4 (8.9)	0.082b	
 Calcineurin/mTOR inhibitors	7 (4.2)	3 (2.5)	4 (8.9)	0.168b	
Diagnosis.no. (%)					
 Proven	133 (80.6)	89 (74.2)	44 (97.8)	< 0.001	
 Probable	27 (16.4)	26 (21.7)	1 (2.2)	< 0.001	
 Possible	5 (3.0)	5 (4.2)	0	0.378 b	
Concurrent (non-lung) site of infection, no (%)					
 CNS	39 (23.6)		39 (86.7)		
 Bloods tream	9 (5.5)		9 (20.0)		
 Bone/joint	2 (1.2)		2 (4.4)		
 Skin	3 (1.8)		3 (6.7)		
Clinical characteristic, no (%)					
 Fever	50 (20.3)	19 (15.2)	31 (68.9)	< 0.001	
 Cough	80 (48.5)	69 (57.5)	11 (24.4)	< 0.001	
 Expectoration	56 (33.9)	48 (38.4)	8 (17.8)	0.012	
 Neurological symptomsd, no (%)	26 (15.8)	0	26 (57.8)	< 0.001	
 Vomit	19 (11.5)	0	19 (42.2)	< 0.001	
 Headache	37 (22.4)	1 (0.8)	36 (80.0)	< 0.001	
 Dyspnea	22 (13.3)	17 (14.2)	5 (11.1)	0.607	
 Chest pain	21 (12.7)	21 (16.8)	0	0.003	
 Skin lesion	5 (3.0)	0	5 (11.1)	< 0.001b	
Time to diagnosis					
 Mean number of days (IQR)	4 (0.5–10)	5 (0.25-10)	3 (0.5-8)	0.515	
Laboratory results					
 WBC (×109/L)	6.77 (5.34–8.92)	6.67 (5.51–8.18)	8.38 ± 4.26	0.074	
 Hb (g/L)	135 (121–148)	142 (131–153)	115 (85.5–125)	< 0.001	
 PLT (×109/L)	213(162.75–268)	222(179–278)	181(108-283.4)	0.002	
 Neutrophilsc (%)	65.95 (58.9–76.9)	63.05(56.23–70.85)	82.5 (71.8-88.65)	< 0.001	
 Lymphocytesc (%)	24.7 (14.40–31.00)	27.75(20.26–33.77)	12.2(5.75–19.6)	< 0.001	
 NLR	2.72 (1.90–5.25)	2.26 (1.61–3.32)	6.7131 (3.61–15.34)	< 0.001	
 Monocytesc (%)	6.43(4.75–8.10)	6.60 (5.18–8.41)	5.50(3.20–7.95)	0.008	
 CRPa	57/136	33/98	24/38	0.002	
 PCTa	38/63	17/35	21/28	0.033	
 ESRa	28/51	15/30	13/21	0.400	
 GLUa	38/155	21/113	17/42	0.005	
Serum CrAg	76/93	65/79	11/14	1.000 b	
CSF CrAg	15/25		15/25		
CSF smear	29/34		29/34		
CSF cluture	8/12		8/12		
Antifungal regimen, no (%)					
 Azole monotherapy	131 (79.4)	112 (93.3)	19 (42.2)	< 0.001	
 Non-azole monotherapy	27 (16.4)	1 (0.8)	26 (57.8)		
 None	11 (6.7)	7 (5.8)	4 (8.9)		
Outcome, no (%)					
Survivors	142 (86.1)	119 (99.2)	23 (51.1)	< 0.001	
Non-survivors	23 (13.9)	1 (0.8)	22 (48.9)		
a. The detection value was higher than the reference range (CRP 0-8 mg/L, PCT 0-0.05ng/ml, ESR 0–20 mm/h, GLU 3.9-6.1mmol/L)

b. Fisher exact probability method

c. Percentage of each type of cell in blood cells

d. Neurological symptoms: hearing loss, vision loss, cognitive impairment, personality change, coma, delirium, epilepsy, etc

Treatment

The lung infection mainly accepts azole monotherapy, while extrapulmonary infection only 19 cases (42.2%) use azole monotherapy. Out of the remaining 26 patients with extrapulmonary infections, 19 patients were subjected to treatment using amphotericin B alone or in conjunction with azoles or in combination with 5-FC. 2 patients were subjected to triple therapy. 4 patients were left untreated as a consequence of either discontinuing their treatment prematurely or the rapid progression of their disease. In addition to antifungal treatment, adjunctive treatment was also provided (Table 3). 11 patients with pulmonary infection underwent lung resection and resection of lesions. In cases of extrapulmonary infection, especially for patients with cryptococcal meningitis, 15 patients were administered high-dose corticosteroids to control inflammation, and 13 patients received serial LP to manage high-pressure and relieve symptoms such as headaches. The mortality of extrapulmonary infection group (48.9%) was significantly higher than that of pulmonary infection group (0.8%).

Table 3 The therapeutic methods of patients with cryptococcosis

Antifungal regimen, no (%)	Total cohort (n = 165)	Pulmonary infection (n = 120)	Extrapulmonary infection (n = 45)	
Amphotericin B + 5FC	6 (3.5)	0	6 (13.3)	
Azole monotherapy	136 (80.0)	112 (93.3)	19 (42.2)	
Amphotericin B monotherapy	2 (1.2)	0	2 (4.4)	
Amphotericin B + azole	12 (7.1)	1 (0.8)	11 (24.4)	
Azole + 5FC	1 (0.6)	0	1 (2.2)	
Triple therapy	2 (1.2)	0	2 (4.4)	
None	11 (6.5)	7 (5.6)	4 (8.9)	
Adjunctive management				
High-dose corticosteroids	15 (8.8)	0	15 (33.3)	
Serial LP	13 (7.6)	0	13 (28.9)	
CSF shunt/ventriculostomy	1 (0.6)	0	1 (2.2)	
Surgical lung resection	12 (7.1)	11 (8.8)	1 (2.2)	

Prognostic analysis

According to univariate Logistic regression analysis, several factors were found to be related to the prognosis of cryptococcosis, including immune status (hazard ratio [HR], 4.476; 95% confidence interval [CI], 1.725–11.618; P = 0.002), infection position ([HR], 113.826; [CI], 14.607-886.967; P < 0.001), white blood cell count, ([HR],1.209;[CI], 1.054–1.386; P = 0.007) ,hemoglobin ([HR], 0.970; [CI], 0.955–0.986; P < 0.001), platelet count ([HR], 0.993; [CI], 0.987–0.999; P = 0.026), neutrophil percentage ([HR], 1.115; [CI], 1.065–1.168; P < 0.001), lymphocyte percentage ([HR], 0.875; [CI], 0.827–0.927; P < 0.001), Neutrophil-to-Lymphocyte Ratio (NLR) ([HR], 1.144; [CI], 1.072–1.221; P < 0.001), Monocyte percentage ([HR], 0.752; [CI], 0.618–0.915; P = 0.004) were related to the prognosis (Table 4). Multivariate logistic regression analysis showed that the infection position remained was related to the prognosis, with statistical significance ([HR], 0.018; [CI], 0.001–0.384; P = 0.001), fasting blood glucose ([HR], 4.359; [CI]1.678–11.325; P = 0.003), and azole monotherapy ([HR], 0.134; [CI], 0.052–0.344; P < 0.001) were related to the prognosis. Further multivariate logistic regression analysis revealed that infection position remained significantly related to the prognosis ([HR], 0.018; [CI], 0.001–0.384; P = 0.010). (Fig. 2).

Table 4 Univariate analysis of factors for cryptococcosis patients prognosis

Variables	P Value	95%CI	
Age	0.222	1.021 (0.988–1.055)	
Male	0.399	1.480 (0.595–3.680)	
Smoking	0.667	1.220 (0.493–3.019)	
Immune status	0.002	4.476 (1.725–11.618)	
Diagnosis of time	0.513	0.977 (0.913–1.047)	
Infection position	< 0.001	113.826 (14.607-886.967)	
WBC	0.007	1.209 (1.054–1.386)	
Hb	< 0.001	0.970 (0.955–0.986)	
PLT	0.026	0.993 (0.987–0.999)	
Nc	< 0.001	1.115 (1.065–1.168)	
Lc	< 0.001	0.875 (0.827–0.927)	
NLR	< 0.001	1.144 (1.072–1.221)	
Mc	0.004	0.752 (0.618–0.915)	
CRPa	0.049	2.743 (1.005–7.484)	
PCTa	0.085	0.385 (0.846–13.544)	
GLUa	0.003	4.359 (1.678–11.325)	
Serum CrAg	0.577	1.846(0.214–15.902)	
Azole monotherapy	< 0.001	0.134 (0.052–0.344)	

Fig. 2 Multivariable analysis of factors for cryptococcosis patient prognosis

Discussion

Cryptococcus is an opportunistic pathogen that invades the lungs through the respiratory tract and gives rise to pulmonary cryptococcosis, which is the most prevalent form of cryptococcosis. When the immune system is compromised, Cryptococcus can breach the pulmonary immune defenses and disseminate to other body sites such as the central nervous system, lymph nodes, bones and joints, and skin, leading to disseminated cryptococcosis.

Cryptococcus is a lethal fungus whose polysaccharide capsules are considered the primary virulence factors [13]. Polysaccharides are immunomodulators, One of their target cell populations for modulation are macrophages, Polysaccharide capsules affect the immune function of macrophages by reducing the antigen presentation function, changing co-stimulatory molecules, regulating the secretion of pro-inflammatory and anti-inflammatory cytokines, and up-regulating the death receptor Fas/FasL to stimulate cell apoptosis [14–18]. Various studies have proved that cryptococcal antigen (CrAg) titer in blood and CSF could act as risk factors for predicting the extent of pulmonary cryptococcosis and outcome in non-HIV patients [19, 20]. We also analyzed the association of CrAg with cryptococcosis, but we found that there was no significant difference between the two groups for CrAg in serum, and no relationship was shown between CrAg and cryptococcosis outcome, which might due to the small size and individual difference.

Macrophages are vital cellular components of innate immunity, serving as the primary barrier against pathogens and regulating homeostasis and inflammatory responses. Macrophages hold an integral role in the defense against Cryptococcus, especially alveolar macrophages (AMs) as first responders, whose surface complement binds to mannose receptors, mediates phagocytosis, clears Cryptococcus or forms inflammatory granulomas to confine Cryptococcus to the lungs [21, 22]. Host cytokines kill Cryptococcus by inducing macrophage polarization. It has been shown that activation of M1 macrophages and downstream Th1 response effectively control Cryptococcus infection [23–26]. In addition, macrophages release high levels of reactive nitrogen intermediates (RNI), nitric oxide, reactive oxygen intermediates(ROI) and superoxide, which damage DNA and a number of chemical moieties of Cryptococcus [27]. Malfunction in macrophage development, activation, proliferation, and signaling collectively contribute to a heightened risk of disseminated cryptococcal infection [28–31]. Monocytes in the blood give rise to macrophages, which escape from blood vessels and infiltrate the tissues following further differentiation. We have observed a statistically significant decrease in the number of monocytes in the extrapulmonary infection group compared to that in the pulmonary infection group, which consequently leads to a secondary decrease in macrophages that could potentially facilitate the development of disseminated cryptococcosis.

NLR is regarded as a diagnostic and predictive marker of disease severity in patients with inflammatory ailments, which can mirror the balance between innate and adaptive immune reactions [32, 33], and the increase in NLR may indicate the inflammatory response to fungal infection, revealing, to some extent, the imbalance between inflammation and immune response in our investigation. Some studies found that an increase in the NLR during treatment may be used as an indicator of treatment failure for patients with cryptococcal meningitis [34]. In HIV-negative immunocompetent cryptococcal meningitis, they got the same conclusion, in addition, they proved the baseline high IgM indicated a low risk of post-infectious inflammatory response syndrome (PIIRS) development during the treatment [35]. lymphopenia and monocytopenia may be risk factors for cryptococcal dissemination [36], which agrees with our study. In our study, the percentage of neutrophils in the extrapulmonary infection group was higher than pulmonary infection group, hemoglobin, platelet count and lymphocyte percentage were lower. And univariate Analysis found that elevated white blood cells and neutrophils, decreased lymphocytes may serve as risk factors for the prognosis of cryptococcosis, which is consistent with the findings of prior investigations [37, 38]. Evidence suggests that neutrophils promote non-specific immunity and initiate the body’s response to inflammation, while lymphocytes are protective elements against inflammation. The increase of white blood cells and neutrophils in patients with cryptococcosis may be closely related to lymphopenia. It is well known that the patients with lymphopenia easily leads to microbial infection which can directly induce the recruitment of neutrophils to tissue sites and further promote the activation of neutrophils, resulting in the increase of the total number of white blood cells and the percentage of neutrophils [39–41]. To a certain extent, we can predict the prognosis by assessing the patient’s condition based on high neutrophils and low lymphocytes. Previous study also has proved that low CRP levels and high haemoglobin levels were risk factors for developing CM in cryptococcemia patients [42]. But in our study, we found that there was no significant difference between the two groups for CRP, and no relationship was shown between CRP and cryptococcosis outcome, which might due to the small size and individual difference.

Tian et al. found that underlying disease, dyskinesia, anemia, high peripheral blood neutrophils, low platelet count, high CSF fungal burden (measured by CrAg titer), and high CSF OP, were independently associated with prognosis in patients infected with ST5 lineage without HIV [20]. The results of another study in HIV-negative CM patients with acute/subacute onset suggest that the ratio of CSF glucose/blood glucose, impaired consciousness, and hospitalization length were indicated to be not only independent prognosis factors, but also factors significantly related to the survival time [43]. In a retrospective analysis of pulmonary cryptococcosis and extrapulmonary cryptococcosis, compared with pulmonary cryptococcosis, a larger proportion of extrapulmonary cryptococcosis patients were found to have immunocompromised conditions, which is consistent with the results of our study. Fever and headache were more common in extrapulmonary cryptococcosis patients [36]. And headache is an independent risk factor for poor prognosis in AIDS patients with cryptococcosis [44]. However, no similar phenomenon was found in our study, which may be for different groups of people, and the sample size can be further increased in the future to strengthen the robustness of the results.

In our study, multivariate analysis showed that extrapulmonary infection was a risk factor for the prognosis of cryptococcosis, and CM accounted for 86.7% of extrapulmonary infection. Breaking through the blood-brain barrier (BBB)is the most critical step in the pathogenesis of CM, current studies have found that Cryptococcus may have three potential traversal pathways to cross the BBB: Transcellular traversal, Trojan horse dissemination and the paracellular pathway [45, 46], and in which the transcellular traversal is primarily main pathway crossing the BBB [45, 47–49]. CD44 expressed on the surface of human brain microvascular endothelial cells (HBMEC) binds to hyaluronic acid in Cryptococcus, causing Cryptococcus to attach to HBMEC [50–53]. It has been shown that the cytoplasmic tail of CD44 interacts with HBMEC cytoskeletal linker proteins, which accumulate actin at the site of infection and promote cytoskeletal rearrangement [50]. Moreover, they found that Rac1 and other GTP-bound small Rho family proteins can regulate host cell actin cytoskeleton [54, 55]. Cryptococcus Plb1 helps fungi cross the BBB by activating host cell Rac1 and its association with STAT3 [56]. Although the mechanism of Cryptococcus entry into HBMEC remains further exploration, these related studies are based on the adhesion of Cryptococcus to HBMEC via hyaluronic acid and CD44, indicating the importance of CD44 in the invasion of Cryptococcus into the BBB. CD44 overexpression has been found in many diseases with abnormal immune status, such as HIV infection, tumors, and autoimmune diseases etc. Overexpression of the CD44 receptor results in heightened sensitivity to hyaluronic acid binding, which in turn promotes the invasiveness of Cryptococcus through the BBB [57–62]. This study reveals that the incidence of abnormal immune status was greater in the group with extrapulmonary infections, particularly in patients with CM, suggesting that abnormal immune status may contribute to central nervous system involvement.

There are several limitations of this study that must be acknowledged. Firstly, Cryptococcal disease was classified as “proven” based on the presence of consistent radiographic abnormalities and culture positivity obtained from sterile fluid or confirmed by biopsy. Unfortunately, the pulmonary puncture technique was not utilized during the early clinical period, which resulted in a miss ed diagnosis of pulmonary cryptococcal infection. Additionally, not all patients were tested for cryptococcal podococcal antigen due to doctors’ empirical consultations, which may have resulted in a missed diagnosis of peripheral blood cryptococcal infection. Secondly, this study involved a limited number of cases, and a large prospective study is needed to further confirm our findings. Finally, since this was a retrospective study, medical records were limited, and some clinical information, such as inflammatory indicators, were missing. However, this did not affect our analysis or final conclusions.

Conclusions

In conclusion, patients with abnormal immune status, decreased lymphocytes and monocytes, and increased neutrophils and NLR are more likely to develop extrapulmonary infection, whether novel exposure or through reactivation of a previously acquired latent infection. CM has a high mortality rate compared with pulmonary cryptococcosis. Timely identification of high-risk groups of CM and preventive antifungal treatment can reduce the incidence of CM. By delving into mechanisms of cryptococcal action that disrupt the BBB, inhibit receptor-ligand binding, and impede the transmission of signaling pathways, as well as by synergizing with antifungal medications, the objective of preventing and treating CM can be attained. This is poised to markedly elevate the prognostic outlook of cryptococcosis and mitigate its mortality.

Acknowledgements

Not applicable.

Author contributions

ZWT, QQP designed this study. YLS and QQP performed the data acquisition. ZWT, CYW and ZH performed data analysis. ZWT, YLS, SCZ and YJ edited the manuscript. YLW and XWZ supervised the present study. All authors read and approved the final manuscript.

Funding

This work was supported by Xiaowu Zhu famous doctor studio under grant NO.CY2019002.

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by The Ethics Committee of The First Affiliated Hospital with Nanjing Medical University. With the approval of the Ethics Committee (protocol 2021-SR-566), informed consent was waived because of the retrospective nature of the study, and the analysis used anonymous clinical data. Clinical trial number: not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ziwei Tao and Qinqin Pu contributed equally to this work and shared first authorship.
==== Refs
References

1. Mohamed SH Nyazika TK Ssebambulidde K Lionakis MS Meya DB Drummond RA Fungal CNS infections in Africa: the Neuroimmunology of Cryptococcal Meningitis Front Immunol 2022 13 804674 10.3389/fimmu.2022.804674 35432326
Mohamed SH, Nyazika TK, Ssebambulidde K, Lionakis MS, Meya DB, Drummond RA. Fungal CNS infections in Africa: the Neuroimmunology of Cryptococcal Meningitis. Front Immunol. 2022;13:804674.35432326
2. Suwatanapongched T Sangsatra W Boonsarngsuk V Watcharananan SP Incharoen P Clinical and radiologic manifestations of pulmonary cryptococcosis in immunocompetent patients and their outcomes after treatment Diagn Interv Radiol 2013 19 6 438 46 23864332
Suwatanapongched T, Sangsatra W, Boonsarngsuk V, Watcharananan SP, Incharoen P. Clinical and radiologic manifestations of pulmonary cryptococcosis in immunocompetent patients and their outcomes after treatment. Diagn Interv Radiol. 2013;19(6):438–46.23864332
3. Sun L Chen H Shao C Song Y Bai C Pulmonary cryptococcosis with trachea wall invasion in an immunocompetent patient: a case report and literature review Respiration 2014 87 4 324 8 10.1159/000357715 24525662
Sun L, Chen H, Shao C, Song Y, Bai C. Pulmonary cryptococcosis with trachea wall invasion in an immunocompetent patient: a case report and literature review. Respiration. 2014;87(4):324–8.24525662
4. Gao LW Jiao AX Wu XR Zhao SY Ma Y Liu G Clinical characteristics of disseminated cryptococcosis in previously healthy children in China BMC Infect Dis 2017 17 1 359 10.1186/s12879-017-2450-5 28532447
Gao LW, Jiao AX, Wu XR, Zhao SY, Ma Y, Liu G, et al. Clinical characteristics of disseminated cryptococcosis in previously healthy children in China. BMC Infect Dis. 2017;17(1):359.28532447
5. Ngan NTT Flower B Day JN Treatment of cryptococcal meningitis: how have we got Here and where are we Going? Drugs 2022 82 12 1237 49 10.1007/s40265-022-01757-5 36112342
Ngan NTT, Flower B, Day JN. Treatment of cryptococcal meningitis: how have we got Here and where are we. Going? Drugs. 2022;82(12):1237–49.36112342
6. Zhu LP Wu JQ Xu B Ou XT Zhang QQ Weng XH Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997–2007 Med Mycol 2010 48 4 570 9 10.3109/13693780903437876 20392150
Zhu LP, Wu JQ, Xu B, Ou XT, Zhang QQ, Weng XH. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997–2007. Med Mycol. 2010;48(4):570–9.20392150
7. Chen J Varma A Diaz MR Litvintseva AP Wollenberg KK Kwon-Chung KJ Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China Emerg Infect Dis 2008 14 5 755 62 10.3201/eid1405.071312 18439357
Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis. 2008;14(5):755–62.18439357
8. Li Z, Liu Y, Cao H, Huang S, Long M. Epidemiology and clinical characteristics of cryptococcal meningitis in China (1981–2013): a review of the literature. Med Mycology: Open Access. 2017;03(01).
9. Zhou L-H Jiang Y-K Li R-Y Huang L-P Yip C-W Denning DW Risk-based Estimate of Human Fungal Disease Burden, China Emerg Infect Dis 2020 26 9 2137 47 10.3201/eid2609.200016 32818410
Zhou L-H, Jiang Y-K, Li R-Y, Huang L-P, Yip C-W, Denning DW, et al. Risk-based Estimate of Human Fungal Disease Burden, China. Emerg Infect Dis. 2020;26(9):2137–47.32818410
10. Setianingrum F Rautemaa-Richardson R Denning D Pulmonary cryptococcosis: a review of pathobiology and clinical aspects Med Mycol 2019 57 2 133 50 10.1093/mmy/myy086 30329097
Setianingrum F, Rautemaa-Richardson R, Denning D. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Med Mycol. 2019;57(2):133–50.30329097
11. Donnelly J Chen S Kauffman C Steinbach W Baddley J Verweij P Revision and update of the Consensus definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Clin Infect Diseases: Official Publication Infect Dis Soc Am 2020 71 6 1367 76 10.1093/cid/ciz1008
Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P, et al. Revision and update of the Consensus definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;71(6):1367–76.
12. Marr K Sun Y Spec A Lu N Panackal A Bennett J A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative people in the United States Clin Infect Diseases: Official Publication Infect Dis Soc Am 2020 70 2 252 61 10.1093/cid/ciz193
Marr K, Sun Y, Spec A, Lu N, Panackal A, Bennett J, et al. A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative people in the United States. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;70(2):252–61.
13. Decote-Ricardo D LaRocque-de-Freitas IF Rocha JDB Nascimento DO Nunes MP Morrot A Immunomodulatory Role of Capsular Polysaccharides constituents of Cryptococcus neoformans Front Med (Lausanne) 2019 6 129 10.3389/fmed.2019.00129 31275938
Decote-Ricardo D, LaRocque-de-Freitas IF, Rocha JDB, Nascimento DO, Nunes MP, Morrot A, et al. Immunomodulatory Role of Capsular Polysaccharides constituents of Cryptococcus neoformans. Front Med (Lausanne). 2019;6:129.31275938
14. Larocque-De-Freitas IF Da Silva-Junior EB Gemieski LP Da Silva Dias Lima B Diniz-Lima I De Carvalho Vivarini A Inhibition of Microbicidal Activity of Canine macrophages DH82 Cell line by Capsular polysaccharides from Cryptococcus neoformans J Fungi 2024 10 5 339 10.3390/jof10050339
Larocque-De-Freitas IF, Da Silva-Junior EB, Gemieski LP, Da Silva Dias Lima B, Diniz-Lima I, De Carvalho Vivarini A, et al. Inhibition of Microbicidal Activity of Canine macrophages DH82 Cell line by Capsular polysaccharides from Cryptococcus neoformans. J Fungi. 2024;10(5):339.
15. Larocque-De-Freitas IF, Rocha JDB, Nunes MP, Oliveira PAV, Nascimento DDO, Freire-De-Lima L et al. Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection. Sci Rep. 2018;8(1).
16. Villena SN Pinheiro RO Pinheiro CS Nunes MP Takiya CM DosReis GA Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand Cell Microbiol 2008 10 6 1274 85 10.1111/j.1462-5822.2008.01125.x 18284419
Villena SN, Pinheiro RO, Pinheiro CS, Nunes MP, Takiya CM, DosReis GA, et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol. 2008;10(6):1274–85.18284419
17. Monari C Paganelli F Bistoni F Kozel TR Vecchiarelli A Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms Cell Microbiol 2008 10 10 2129 37 10.1111/j.1462-5822.2008.01196.x 18647312
Monari C, Paganelli F, Bistoni F, Kozel TR, Vecchiarelli A. Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cell Microbiol. 2008;10(10):2129–37.18647312
18. Monari C Pericolini E Bistoni G Casadevall A Kozel TR Vecchiarelli A Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages J Immunol 2005 174 6 3461 8 10.4049/jimmunol.174.6.3461 15749881
Monari C, Pericolini E, Bistoni G, Casadevall A, Kozel TR, Vecchiarelli A. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages. J Immunol. 2005;174(6):3461–8.15749881
19. Lin C, Yang TY, Chan MC, Hsu KH, Huang YH, Tseng JS. Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV patients. J Fungi (Basel). 2021;7(8).
20. Tian Y Wang J Shen Y Zhao J Hu J Zhu X Characteristics and prognostic risk factors of patients with sequence type 5 lineage-associated cryptococcosis in China Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis 2023 128 244 53
Tian Y, Wang J, Shen Y, Zhao J, Hu J, Zhu X, et al. Characteristics and prognostic risk factors of patients with sequence type 5 lineage-associated cryptococcosis in China. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2023;128:244–53.
21. Redlich S Ribes S Schütze S Eiffert H Nau R Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells J Neuroinflammation 2013 10 71 10.1186/1742-2094-10-71 23738865
Redlich S, Ribes S, Schütze S, Eiffert H, Nau R. Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells. J Neuroinflammation. 2013;10:71.23738865
22. Wang DX Zhang Q Wen QT Ding GX Wang YG Du FX Comparison of CT findings and histopathological characteristics of pulmonary cryptococcosis in immunocompetent and immunocompromised patients Sci Rep 2022 12 1 5712 10.1038/s41598-022-09794-6 35383254
Wang DX, Zhang Q, Wen QT, Ding GX, Wang YG, Du FX, et al. Comparison of CT findings and histopathological characteristics of pulmonary cryptococcosis in immunocompetent and immunocompromised patients. Sci Rep. 2022;12(1):5712.35383254
23. Hardison SE Herrera G Young ML Hole CR Wozniak KL Wormley FL Jr. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation J Immunol 2012 189 8 4060 8 10.4049/jimmunol.1103455 22984078
Hardison SE, Herrera G, Young ML, Hole CR, Wozniak KL, Wormley FL. Jr. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J Immunol. 2012;189(8):4060–8.22984078
24. De Leon-Rodriguez CM Rossi DCP Fu MS Dragotakes Q Coelho C Guerrero Ros I The outcome of the Cryptococcus neoformans-Macrophage Interaction depends on phagolysosomal membrane Integrity J Immunol 2018 201 2 583 603 10.4049/jimmunol.1700958 29858266
De Leon-Rodriguez CM, Rossi DCP, Fu MS, Dragotakes Q, Coelho C, Guerrero Ros I, et al. The outcome of the Cryptococcus neoformans-Macrophage Interaction depends on phagolysosomal membrane Integrity. J Immunol. 2018;201(2):583–603.29858266
25. Alvarez M Casadevall A Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages BMC Immunol 2007 8 1 16 10.1186/1471-2172-8-16 17705844
Alvarez M, Casadevall A. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol. 2007;8(1):16.17705844
26. Chrisman CJ Albuquerque P Guimaraes AJ Nieves E Casadevall A Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages PLoS Pathog 2011 7 5 e1002047 10.1371/journal.ppat.1002047 21637814
Chrisman CJ, Albuquerque P, Guimaraes AJ, Nieves E, Casadevall A. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog. 2011;7(5):e1002047.21637814
27. Nathan C Shiloh MU Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens Proc Natl Acad Sci U S A 2000 97 16 8841 8 10.1073/pnas.97.16.8841 10922044
Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A. 2000;97(16):8841–8.10922044
28. Leopold Wager CM Hole CR Wozniak KL Olszewski MA Wormley FL Jr. STAT1 signaling is essential for protection against Cryptococcus neoformans infection in mice J Immunol 2014 193 8 4060 71 10.4049/jimmunol.1400318 25200956
Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Wormley FL. Jr. STAT1 signaling is essential for protection against Cryptococcus neoformans infection in mice. J Immunol. 2014;193(8):4060–71.25200956
29. Leopold Wager CM Hole CR Wozniak KL Olszewski MA Mueller M Wormley FL Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans Infect Immun 2015 83 12 4513 27 10.1128/IAI.00935-15 26351277
Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Mueller M, Wormley FL. Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Infect Immun. 2015;83(12):4513–27.26351277
30. Campuzano A, Castro-Lopez N, Martinez AJ, Olszewski MA, Ganguly A, Leopold Wager C et al. CARD9 is required for classical macrophage activation and the induction of protective immunity against Pulmonary Cryptococcosis. mBio. 2020;11(1).
31. Viola GM Malek AE Rosen LB DiNardo AR Nishiguchi T Okhuysen PC Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: an underappreciated association Mycoses 2021 64 6 576 82 10.1111/myc.13247 33476401
Viola GM, Malek AE, Rosen LB, DiNardo AR, Nishiguchi T, Okhuysen PC, et al. Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: an underappreciated association. Mycoses. 2021;64(6):576–82.33476401
32. Han Q Wen X Wang L Han X Shen Y Cao J Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms J Clin Lab Anal 2020 34 5 e23191 10.1002/jcla.23191 31901184
Han Q, Wen X, Wang L, Han X, Shen Y, Cao J, et al. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. J Clin Lab Anal. 2020;34(5):e23191.31901184
33. Liu S Wang X She F Zhang W Liu H Zhao X Effects of Neutrophil-to-lymphocyte ratio combined with Interleukin-6 in Predicting 28-Day mortality in patients with Sepsis Front Immunol 2021 12 639735 10.3389/fimmu.2021.639735 33796105
Liu S, Wang X, She F, Zhang W, Liu H, Zhao X. Effects of Neutrophil-to-lymphocyte ratio combined with Interleukin-6 in Predicting 28-Day mortality in patients with Sepsis. Front Immunol. 2021;12:639735.33796105
34. Zhang K Li H Zhang L Liao W Cai L Li X The change in the Neutrophil/Lymphocyte ratio predicts the prognosis of patients with cryptococcal meningitis Mycopathologia 2021 186 6 857 62 10.1007/s11046-021-00553-1 34467475
Zhang K, Li H, Zhang L, Liao W, Cai L, Li X, et al. The change in the Neutrophil/Lymphocyte ratio predicts the prognosis of patients with cryptococcal meningitis. Mycopathologia. 2021;186(6):857–62.34467475
35. Wang Y Wei H Shen L Su X Liu J Xu X Immunological predictors of Post Infectious Inflammatory Response Syndrome in HIV-Negative immunocompetent cryptococcal meningitis Front Immunol 2022 13 895456 10.3389/fimmu.2022.895456 35686135
Wang Y, Wei H, Shen L, Su X, Liu J, Xu X, et al. Immunological predictors of Post Infectious Inflammatory Response Syndrome in HIV-Negative immunocompetent cryptococcal meningitis. Front Immunol. 2022;13:895456.35686135
36. Shi J Chen J Hu L Ma AHY Hu H Wang C Retrospective analysis of pulmonary cryptococcosis and extrapulmonary cryptococcosis in a Chinese tertiary hospital BMC Pulm Med 2023 23 1 277 10.1186/s12890-023-02578-2 37501136
Shi J, Chen J, Hu L, Ma AHY, Hu H, Wang C, et al. Retrospective analysis of pulmonary cryptococcosis and extrapulmonary cryptococcosis in a Chinese tertiary hospital. BMC Pulm Med. 2023;23(1):277.37501136
37. Mednick AJ Feldmesser M Rivera J Casadevall A Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis Eur J Immunol 2003 33 6 1744 53 10.1002/eji.200323626 12778493
Mednick AJ, Feldmesser M, Rivera J, Casadevall A. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol. 2003;33(6):1744–53.12778493
38. Wozniak KL Kolls JK Wormley FL Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by gamma/delta T cells BMC Immunol 2012 13 1 65 10.1186/1471-2172-13-65 23216912
Wozniak KL, Kolls JK, Wormley FL. Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by gamma/delta T cells. BMC Immunol. 2012;13(1):65.23216912
39. Hazeldine J Lord J Neutrophils and COVID-19: active participants and rational therapeutic targets Front Immunol 2021 12 680134 10.3389/fimmu.2021.680134 34149717
Hazeldine J, Lord J. Neutrophils and COVID-19: active participants and rational therapeutic targets. Front Immunol. 2021;12:680134.34149717
40. Yang L Liu S Liu J Zhang Z Wan X Huang B COVID-19: immunopathogenesis and immunotherapeutics Signal Transduct Target Therapy 2020 5 1 128 10.1038/s41392-020-00243-2
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Therapy. 2020;5(1):128.
41. Xu Z Shi L Wang Y Zhang J Huang L Zhang C Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respiratory Med 2020 8 4 420 22 10.1016/S2213-2600(20)30076-X
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med. 2020;8(4):420–22.
42. Zhao H Zhou M Zheng Q Zhu M Yang Z Hu C Clinical features and outcomes of Cryptococcemia patients with and without HIV infection Mycoses 2021 64 6 656 67 10.1111/myc.13261 33609302
Zhao H, Zhou M, Zheng Q, Zhu M, Yang Z, Hu C, et al. Clinical features and outcomes of Cryptococcemia patients with and without HIV infection. Mycoses. 2021;64(6):656–67.33609302
43. Zheng H Chen Q Xie Z Wang D Li M Zhang X A retrospective research of HIV-negative cryptococcal meningoencephalitis patients with acute/subacute onset Eur J Clin Microbiol Infect Dis 2016 35 2 299 303 10.1007/s10096-015-2545-0 26792138
Zheng H, Chen Q, Xie Z, Wang D, Li M, Zhang X, et al. A retrospective research of HIV-negative cryptococcal meningoencephalitis patients with acute/subacute onset. Eur J Clin Microbiol Infect Dis. 2016;35(2):299–303.26792138
44. Liu S Chen W Cheng F Ye X Pan N Lu H Clinical characteristics and prognostic factors of 60 patients with acquired immune deficiency syndrome combined with Cryptococcus neoformans BMC Infect Dis 2023 23 1 204 10.1186/s12879-023-08137-8 37024795
Liu S, Chen W, Cheng F, Ye X, Pan N, Lu H. Clinical characteristics and prognostic factors of 60 patients with acquired immune deficiency syndrome combined with Cryptococcus neoformans. BMC Infect Dis. 2023;23(1):204.37024795
45. Chang Y Stins M McCaffery M Miller G Pare D Dam T Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier Infect Immun 2004 72 9 4985 95 10.1128/IAI.72.9.4985-4995.2004 15321990
Chang Y, Stins M, McCaffery M, Miller G, Pare D, Dam T, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun. 2004;72(9):4985–95.15321990
46. Stie J Fox D Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin Microbiology 2012 158 240 58 10.1099/mic.0.051524-0 21998162
Stie J, Fox D. Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology. 2012;158:240–58.21998162
47. Liu T Perlin D Xue C Molecular mechanisms of cryptococcal meningitis Virulence 2012 3 2 173 81 10.4161/viru.18685 22460646
Liu T, Perlin D, Xue C. Molecular mechanisms of cryptococcal meningitis. Virulence. 2012;3(2):173–81.22460646
48. Sabiiti W May R Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells PLoS ONE 2012 7 4 e35455 10.1371/journal.pone.0035455 22530025
Sabiiti W, May R. Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. PLoS ONE. 2012;7(4):e35455.22530025
49. Jong A Wu C Gonzales-Gomez I Kwon-Chung K Chang Y Tseng H Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection J Biol Chem 2012 287 19 15298 306 10.1074/jbc.M112.353375 22418440
Jong A, Wu C, Gonzales-Gomez I, Kwon-Chung K, Chang Y, Tseng H, et al. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem. 2012;287(19):15298–306.22418440
50. Jong A Wu C-H Shackleford GM Kwon-Chung KJ Chang YC Chen H-M Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells Cell Microbiol 2008 10 6 1313 26 10.1111/j.1462-5822.2008.01128.x 18248627
Jong A, Wu C-H, Shackleford GM, Kwon-Chung KJ, Chang YC, Chen H-M, et al. Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol. 2008;10(6):1313–26.18248627
51. Huang SH Long M Wu CH Kwon-Chung KJ Chang YC Chi F Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3) J Biol Chem 2011 286 40 34761 9 10.1074/jbc.M111.219378 21693704
Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, et al. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem. 2011;286(40):34761–9.21693704
52. Long M Huang SH Wu CH Shackleford GM Jong A Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells J Biomed Sci 2012 19 1 19 10.1186/1423-0127-19-19 22316086
Long M, Huang SH, Wu CH, Shackleford GM, Jong A. Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells. J Biomed Sci. 2012;19(1):19.22316086
53. Jong A Wu CH Chen HM Luo F Kwon-Chung KJ Chang YC Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection Eukaryot Cell 2007 6 8 1486 96 10.1128/EC.00120-07 17545316
Jong A, Wu CH, Chen HM, Luo F, Kwon-Chung KJ, Chang YC, et al. Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell. 2007;6(8):1486–96.17545316
54. Chang YC Stins MF McCaffery MJ Miller GF Pare DR Dam T Cryptococcal yeast cells invade the Central Nervous System via Transcellular Penetration of the blood-brain barrier Infect Immun 2004 72 9 4985 95 10.1128/IAI.72.9.4985-4995.2004 15321990
Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, et al. Cryptococcal yeast cells invade the Central Nervous System via Transcellular Penetration of the blood-brain barrier. Infect Immun. 2004;72(9):4985–95.15321990
55. Kim KS Mechanisms of microbial traversal of the blood–brain barrier Nat Rev Microbiol 2008 6 8 625 34 10.1038/nrmicro1952 18604221
Kim KS. Mechanisms of microbial traversal of the blood–brain barrier. Nat Rev Microbiol. 2008;6(8):625–34.18604221
56. Maruvada R Zhu L Pearce D Zheng Y Perfect J Kwon-Chung KJ Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier Cell Microbiol 2012 14 10 1544 53 10.1111/j.1462-5822.2012.01819.x 22646320
Maruvada R, Zhu L, Pearce D, Zheng Y, Perfect J, Kwon-Chung KJ, et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol. 2012;14(10):1544–53.22646320
57. He X Shi X Puthiyakunnon S Zhang L Zeng Q Li Y CD44-mediated monocyte transmigration across Cryptococcus neoformans-infected brain microvascular endothelial cells is enhanced by HIV-1 gp41-I90 ectodomain J Biomed Sci 2016 23 28 10.1186/s12929-016-0247-2 26897523
He X, Shi X, Puthiyakunnon S, Zhang L, Zeng Q, Li Y, et al. CD44-mediated monocyte transmigration across Cryptococcus neoformans-infected brain microvascular endothelial cells is enhanced by HIV-1 gp41-I90 ectodomain. J Biomed Sci. 2016;23:28.26897523
58. Deboux C Ladraa S Cazaubon S Ghribi-Mallah S Weiss N Chaverot N Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates their invasion of perivascular tissues in vivo PLoS ONE 2013 8 2 e57430 10.1371/journal.pone.0057430 23468987
Deboux C, Ladraa S, Cazaubon S, Ghribi-Mallah S, Weiss N, Chaverot N, et al. Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates their invasion of perivascular tissues in vivo. PLoS ONE. 2013;8(2):e57430.23468987
59. Hiscox S Baruha B Smith C Bellerby R Goddard L Jordan N Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan BMC Cancer 2012 12 458 10.1186/1471-2407-12-458 23039365
Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 2012;12:458.23039365
60. Hou C Ishi Y Motegi H Okamoto M Ou Y Chen J Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas J Neurooncol 2019 145 2 201 10 10.1007/s11060-019-03288-8 31506754
Hou C, Ishi Y, Motegi H, Okamoto M, Ou Y, Chen J, et al. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas. J Neurooncol. 2019;145(2):201–10.31506754
61. Liu Y Wu T Lu D Zhen J Zhang L CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer Int J Biol Markers 2018 33 3 308 13 10.1177/1724600817746951 29683068
Liu Y, Wu T, Lu D, Zhen J, Zhang L. CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer. Int J Biol Markers. 2018;33(3):308–13.29683068
62. Grisar J Munk M Steiner CW Amoyo-Minar L Tohidast-Akrad M Zenz P Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis Clin Exp Rheumatol 2012 30 1 64 72 22261341
Grisar J, Munk M, Steiner CW, Amoyo-Minar L, Tohidast-Akrad M, Zenz P, et al. Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(1):64–72.22261341
